{
    "title": "Lanosterol vs Cataracts",
    "inventor_name": "Kang Zhang",
    "publication_year": 2015,
    "device_name": "Lanosterol eye-drop formulation",
    "goal": "Non-surgical dissolution or reversal of cataract opacity to restore lens transparency and vision.",
    "problem_addressed": "Cataracts - protein aggregation in the eye lens that causes clouding and blindness, currently treated only by surgical lens replacement.",
    "concept_summary": "A naturally occurring steroid, lanosterol, is formulated as an ophthalmic eye-drop. Pre-clinical studies in rabbit lenses and cataract-prone dogs showed that repeated administration reduces protein aggregation, clears lens opacity and improves visual function. The approach aims to replace or supplement cataract surgery with a pharmacological therapy.",
    "detailed_description": "Zhang and colleagues identified mutations in the lanosterol synthase (LSS) gene that prevent endogenous lanosterol production and lead to congenital cataracts. They prepared a lanosterol solution and applied it to isolated rabbit lenses in vitro for six days, achieving clarity in 11 of 13 samples. In vivo, dogs received twice-daily eye-drops for six weeks; three of seven dogs showed complete vision restoration and the remaining four exhibited partial improvement. The researchers plan human trials to determine safety and efficacy. A related patent describes a method for extracting lanosterol from lanolin alcohol, indicating a potential production route.",
    "principles": [
        "Steroid-mediated disruption of lens protein aggregates",
        "Restoration of lens transparency via solubilization of crystallin clumps"
    ],
    "scientific_domains": [
        "Ophthalmology",
        "Biochemistry",
        "Pharmacology"
    ],
    "mechanisms_of_action": [
        "Lanosterol interferes with hydrophobic interactions that cause crystallin aggregation",
        "Promotes refolding or clearance of misfolded lens proteins"
    ],
    "materials": [
        "Lanosterol (steroid)",
        "Methanol",
        "Acetone",
        "Lanolin alcohol (as a source of lanosterol in the patent)"
    ],
    "energy_sources": [],
    "inputs": [
        "Lanosterol eye-drop solution",
        "Topical administration to the ocular surface"
    ],
    "outputs": [
        "Reduced cataract severity",
        "Increased lens transparency",
        "Improved visual acuity"
    ],
    "claimed_performance": "Effective in 11 of 13 rabbit lenses (in vitro) and cleared vision in 3 of 7 dogs, with partial improvement in the remaining four after six weeks of twice-daily dosing.",
    "experimental_evidence": "Animal studies demonstrated that lanosterol solution cleared protein aggregates in dissected rabbit lenses and improved lens transparency in dogs with naturally occurring cataracts. No human data were presented.",
    "replication_status": "No independent replication reported; results are limited to the authors' pre-clinical studies.",
    "keywords": [
        "Lanosterol",
        "Cataract",
        "Eye drop",
        "Protein aggregation",
        "Lens transparency",
        "Ophthalmic drug",
        "Non-surgical cataract treatment"
    ],
    "related_technologies": [
        "Standard cataract surgery (phacoemulsification)",
        "Other pharmacological anti-cataract agents",
        "Lens protein chaperone therapies"
    ],
    "controversy_level": "low",
    "confidence_score": 0.9,
    "practicability_score": 0.6,
    "fringe_score": 0.2,
    "evidence_strength": 0.5,
    "risk_score": 0.2,
    "trl_estimate": 4,
    "source_urls": [
        "http://www.rt.com/usa/310909-cataract-dissolving-eyedrops-study/",
        "http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14650.html",
        "http://www.latimes.com/science/sciencenow/la-sci-sn-cataracts-drops-20150722-story.html"
    ],
    "organizations": [
        "University of California, San Diego (UCSD)",
        "Shiley Eye Institute",
        "National Eye Institute (NEI)"
    ],
    "applications": [
        "Therapeutic treatment of existing cataracts",
        "Prevention of cataract formation in at-risk populations"
    ],
    "limitations": [
        "Results limited to short-term animal studies",
        "Potential for cataract redevelopment after treatment cessation",
        "No human clinical data yet"
    ],
    "open_questions": [
        "Exact molecular mechanism by which lanosterol dissolves protein aggregates",
        "Long-term safety and toxicity in humans",
        "Optimal dosing regimen and formulation for human eyes"
    ],
    "red_flags": [
        "Lack of independent replication",
        "Claims of \"reversal\" based on limited animal data",
        "Potential over-optimism without human trial evidence"
    ],
    "evidence_quotes": [
        "The lanosterol solution had an effect on 11 of the 13 animals.",
        "Three dogs' vision was cleared by the eye drops, while the other four showed improvement after six weeks of treatment.",
        "Because the study only lasted for a few months, the cataracts are likely to redevelop.",
        "Lanosterol treatment could reduce cataract severity and increase transparency in dissected rabbit cataractous lenses in vitro and cataract severity in vivo in dogs.",
        "The researchers concluded that the steroid had a connection with the appearance of cataracts."
    ],
    "category": "Medical & Dental Technologies"
}